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Abstract
Proton pump inhibitors (PPIs) represent a milestone 
in the treatment of acid-related diseases, and are the 
mainstay in preventing upper gastrointestinal bleeding 
in high-risk patients treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) or low-dose aspirin. 
However, this beneficial effect does not extend to the 
lower gastrointestinal tract. PPIs do not prevent NSAID 
or aspirin-associated lower gastrointestinal bleeding 
(LGB). PPIs may increase both small bowel injury 
related to NSAIDs and low-dose aspirin treatment and 
the risk of LGB. Recent studies suggested that altering 
intestinal microbiota by PPIs may be involved in the 
pathogenesis of NSAID-enteropathy. An increase in 
LGB hospitalization rates may occur more frequently 
in older patients with more comorbidities and are 
associated with high hospital resource utilization, 
longer hospitalization, and increased mortality. 
Preventive strategies for NSAID and aspirin-associated 
gastrointestinal bleeding should be directed toward 
preventing both upper and lower gastrointestinal 
damage. Future research should be directed toward 
identifying patients at low-risk for gastrointestinal 
events associated with the use of NSAIDs or aspirin to 
avoid inappropriate PPI prescribing. Alternatively, the 
efficacy of new pharmacologic strategies should be 
evaluated in high-risk groups, with the aim of reducing 
the risk of both upper and lower gastrointestinal 
bleeding in these patients.
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Core tip: Proton pump inhibitors (PPIs) reduce the risk 
of upper, but not lower gastrointestinal bleeding (LGB) 
in patients receiving nonsteroidal anti-inflammatory 
drugs (NSAIDs) or low-dose aspirin. PPIs could 
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EDITORIAL
Protons pump inhibitor treatment and lower gastrointestinal 
bleeding: Balancing risks and benefits
Alberto Lué, Angel Lanas
exacerbate small bowel damage related to NSAIDs and 
low-dose aspirin, which contributes to an increased risk 
of LGB possibly related to pathological modifications 
of small bowel microbiota. LGB is a life-threatening 
condition, especially in older patients with comorbidities 
treated with NSAIDs, aspirin, or anticoagulants. No 
accepted treatments exist for decreasing the risk of 
LGB in these patients. Future research is needed on 
reducing inappropriate PPI use and evaluating possible 
pharmacologic interventions to decrease the risk of 
gastrointestinal bleeding.
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INTRODUCTION
Proton pump inhibitors (PPIs) are one of the most 
prescribed drugs worldwide. PPIs are used to treat acid-
related disorders like gastro-esophageal reflux disease 
peptic ulcer, peptic ulcer bleeding, and Helicobacter 
pylori infection when combined with antibiotics. PPIs 
should also be considered in any patient with risk 
factors for gastrointestinal bleeding who receives 
treatment with nonsteroidal anti-inflammatory drugs 
(NSAIDs) or prophylaxis for cardiovascular events with 
aspirin or other antiplatelet agents[1].
Treatment with NSAIDs, low-dose aspirin, other 
antiplatelet drugs, and anticoagulation are associated 
with an increased risk of both upper and lower 
gastrointestinal bleeding (LGB). Concomitant treatment 
with these compounds and PPIs has been associated 
with a decreased risk of upper gastrointestinal bleeding 
(UGB) but, obviously, not with an increased risk of LGB. 
The beneficial effect of PPIs is not expected to occur 
beyond the duodenum because NSAID-gastropathy, 
but not NSAID-enteropathy, is a pH-dependent 
phenomenon and gastroduodenal mucosal protection 
by PPIs is due mainly to their antisecretory effects[2].
PROTON PUMP INHIBITOR 
TREATMENT AND RISK OF LOWER 
GASTROINTESTINAL BLEEDING
In a recent case-control study that included 1008 
patients hospitalized for gastrointestinal bleeding, 
treatment with NSAIDs, low-dose aspirin, other 
antiplatelet agents, and anticoagulants increased the 
risk of both UGB and LGB. In this work, concomitant 
use of PPI was associated with a reduced risk of UGB 
but not LGB[3]. In fact, there was a significant increase 
in the risk of LGB with PPI use, which has also been 
detected by other authors[3-8]. Due to the intrinsic nature 
of observational studies, the finding was explained as 
probably due to a “confounding by indication” bias. 
PPI use could be a marker of a group of patients that 
have an increased risk of LGB because of their clinical 
characteristics rather than the PPI use itself[3]. In a 
previous study, we observed that among patients on 
dual antiplatelet treatment who received concomitant 
PPI treatment, gastrointestinal bleeding events were 
more frequent in the lower gastrointestinal tract 
(74% vs 26%)[9]. There are several potential reasons 
explaining this change in the pattern of gastrointestinal 
events, which include (1) a very high protective effect of 
PPIs on the gastroduodenal mucosa associated with a 
profound decrease in the rate of UGB and a relative (but 
not absolute) increase in the proportion of LGB in low-
dose ascorbic acid users; (2) an absence of the mucosal 
protective effect of PPIs beyond the duodenum; (3) a 
direct harmful effect of low-dose aspirin on the small 
bowel; (4) promotion of bleeding of pre-existing lesions 
by these compounds; and (5) exacerbation of NSAID- 
and aspirin-enteropathy by PPI treatment[10-14].
Lately, a hypothesis proposed that PPIs exacerbate 
NSAID and low-dose aspirin-associated small bowel 
injury by inducing changes in the intestinal micro-
biota[15-17]. A multicenter, cross-sectional study including 
data collected from endoscopic capsule explorations 
from 205 patients treated with low-dose aspirin for 3 
mo showed that 57.6% of patients had at least one 
mucosal lesion. In the multivariate analysis, concomitant 
PPI use (OR = 2.04; 95%CI: 1.05-3.97) and use of 
enteric-coated aspirin (OR = 4.05; 95%CI: 1.49-11.0) 
were independent risk factors for the presence of 
mucosal injury[8]. Similar results were observed in 
patients receiving NSAIDs. In a recent randomized 
clinical trial, 57 healthy volunteers were allocated to 
receive celecoxib plus placebo or rabeprazole for 2 wk. 
The patients were evaluated by capsule endoscopy at 
the start and end of treatment. In the PPI group, the 
authors observed an increased rate of small bowel 
injury (44.7% vs 16.7%, P = 0.04)[6]. 
Some authors suggest that acid gastric suppression 
induced by PPI treatment is related to changes in small 
bowel microbiota and explain, at least in part, NSAID-
induced enteropathy. It is well known that in addition to 
bile acids[18] and inhibition of cyclooxygenase activity[19], 
bacterial mucosal translocation and the consequent 
activation of the innate inflammatory cascade are 
important factors in the pathogenesis of NSAID-
enteropathy[20,21]. In an animal model, Wallace et al[17] 
demonstrated that concomitant treatment with PPIs 
and NSAIDs resulted in a higher rate of small bowel 
mucosal ulceration and bleeding. The authors observed 
that PPI treatment was related to a modification in the 
small bowel microbiota, consisting of a decrease in 
jejunal Actinobacteria and Bifidobacteria spp. In this 
study, the restoration of physiologic microbiota with 
probiotic treatment prevented intestinal injury[17].
Similar findings have been observed in human 
subjects. A small randomized clinical trial, including 25 
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patients treated with low-dose enteric-coated aspirin 
and omeprazole randomized to either placebo or 
probiotic treatment with Lactobacillus casei for 3 mo, 
observed that patients in the probiotic group had a 
significant decrease in the number of mucosal breaks 
when evaluated by capsule endoscopy (P = 0.039)[15].
All these data suggest that PPI treatment not only 
does not protect the lower gastrointestinal tract from 
NSAID- and aspirin-related injury, but that they may 
increase the intestinal mucosal damage and the risk 
of LGB. We observed that the LGB hospitalization rate 
has increased significantly in the past years[9,12,13]. 
These LGB events occur more frequently in older 
patients, who usually have a higher number of 
comorbidities, and are associated with a longer hospital 
stay and higher mortality rates[12]. These events are 
associated with greater use of hospital resources 
and also complicate the management of patients at 
discharge[12]. A considerable percentage of patients 
did not resume prophylactic treatment with low-dose 
aspirin or anticoagulants after an acute episode of LGB, 
increasing the risk of serious cardiovascular events[22]. 
A recent retrospective analysis including 295 patients 
with a previous diagnosis of LGB and low-dose aspirin 
observed that discontinuing low-dose aspirin is related 
to a decreased risk in LGB recurrence (6.9% vs 18.9%; 
P = 0.007), but increased the rates of mortality (26.7% 
vs 8.2%, P = 0.001) and cardiovascular events (36.5% 
vs 22.8%, P = 0.017)[23]. This study is a clear example 
of how difficult it is to find the right balance between 
risks and benefits in these patients. On one side, there 
is a need to reduce or prevent cardiovascular events 
and on the other side there is an increased risk of LGB.
BALANCING RISK AND BENEFITS OF 
PROTON PUMP INHIBITOR TREATMENT
Current clinical practice faces several dilemmas in 
patients who need NSAIDs or aspirin, since damage 
to the upper gastrointestinal tract must be prevented 
without injuring the lower gastrointestinal tract. This 
clinical dilemma is especially important in patients 
who need, for example, preventive treatments against 
cardiovascular disease and who have had a previous 
LGB episode. Alternative therapeutic approaches with 
non-aspirin antiplatelet agents poses a similar risk of 
LGB as aspirin and many not be a valid option[3]. The 
same is true for patients who need NSAIDs, although 
COX-2 selective NSAIDs have been shown to be less 
damaging to the lower gastrointestinal tract than 
traditional NSAIDs[2,11,24]. The addition of a PPI to 
celecoxib increases intestinal mucosal damage[6,10,17]. 
Therefore, future efforts must concentrate on finding 
strategies that help clinicians in the decision making 
process. The first relevant issue is to improve overall 
PPI prescribing and avoid use of PPIs in patients at low 
risk of gastrointestinal complications who take NSAIDs, 
aspirin, other antiplatelet agents, or anticoagulants. 
PPIs are prescribed too often in routine clinical practice, 
where at least 50% of prescriptions are for non-
approved indications[25]. Therefore, the first step should 
be to promote the proper use of these drugs. Identifying 
patients at low risk of gastrointestinal events who 
may not benefit from treatment with PPIs is essential. 
Tools that could help physicians in the decision making 
process are now available[26]. On the other hand, we 
have to reconsider whether current guidelines are 
valid or respond to problems in daily clinical practice. 
For example, the PPI treatment indication in patients 
receiving NSAIDs is based on data from clinical trials of 
chronic NSAID users. However, observational studies 
suggest that the risk of gastrointestinal bleeding may 
be higher when the drug use is recent, and most 
patients take these drugs for short periods of time[11]. 
We also need more evidence to evaluate the risks of 
upper and lower gastrointestinal bleeding with new 
antiplatelet drugs, new oral direct anticoagulants, and 
the multiple combinations available in order to better 
assess the risks and benefits.
On the other hand, in patients at high risk for LGB, 
preventive strategies are needed. This group includes 
older patients, with a great number of comorbidities 
who need more complex management[9,12,23]. As 
mentioned above, in these patients LGB represents a 
serious and life threatening complication. Currently, 
there is no clear effective pharmacological treatment 
to prevent LGB in NSAID, aspirin, or anticoagulant 
users. Some studies have evaluated the effect of the 
prostaglandin analogue misoprostol on small bowel 
injury induced by NSAIDs[7,27]. Other mucosal prote-
ctants such as rebamipide[28-31], irsogladine[32,33], or 
geranylgeranylacetone[34,35] have been tested and are 
only available in the Asia-Pacific region. Their potential 
beneficial effects in these patients still need to be 
evaluated in new studies.
In the same way, some studies have evaluated the 
efficacy of probiotics in preventing lower gastrointestinal 
tract injury among patients treated with NSAIDs or low-
dose aspirin[15,16]. The probiotic administered in these 
two trials was Lactobacillus casei in patient treated with 
low-dose aspirin, while patient treated with NSAIDs 
received the probiotic mixture VSL#3®, that includes 
Streptococcus thermophilus, Bifidobacterium breve, 
Bifidobacterium longum, Bifidobacterium infantis, 
Lactobacillus paracasei, Lactobacillus delbrueckii subsp. 
Bulgaricus, Lactobacillus acidophilus and Lactobacillus 
plantarum[15,16]. The results are promising and suggest 
that pharmacological prophylaxis could be provided 
by this strategy. However, more studies with a larger 
number of patients are also needed. At present, there 
is not sufficient evidence to recommend a specific 
probiotic strain to prevent lower gastrointestinal 
injury. However some bacteria have demonstrated 
antiinflammatory activity and a protective effect on 
intestinal mucosa. For example: (1) Lactobacillus GG 
protect mucosal cells from apoptosis and increase 
mucosal integrity; (2) Lactobacillus plantarum 
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promotes mucine from epithelial cells; (3) Lactobacillus 
reuterii and Lactobacillus casei have demonstrated 
to suppress tumor necrosis factor production in vivo; 
and (4) Streptococcus thermophillus and Lactobacillus 
acidophilus could prevent bacterial translocation[36].
CONCLUSION
In conclusion, PPIs represent a milestone in the 
treatment of acid-related disease. Moreover, PPIs 
significantly reduce the risk of UGB in patients treated 
with NSAIDs, low-dose aspirin, other antiplatelet agents, 
or anticoagulants. This beneficial effect is not observed 
in the lower gastrointestinal tract. Furthermore, recent 
studies suggest that PPIs may in fact increase small 
bowel injury and contribute to the observed increase 
of LGB in the past years; however, results are contro-
versial. Clinicians very often face clinical dilemmas and 
need to balance the risks and benefits of treatment. 
The use of aspirin in preventing cardiovascular disease 
and the risk of gastrointestinal bleeding is one of 
these situations. The dilemma is even more difficult to 
resolve when one of the drugs (PPI) can have a dual 
and opposite effect (beneficial to the upper GI tract 
but damaging to the lower GI tract). Clinicians have 
to evaluate carefully the risk of upper gastrointestinal 
bleeding in patients that have a previous episode of LGB 
in order to discontinue inappropriate administration of 
PPI. Future research should be focused on identifying 
patients at low risk for upper gastrointestinal bleeding 
to avoid inappropriate PPI treatment and to evaluate 
the efficacy of new pharmacologic strategies in high-
risk groups. The aim of this strategy is to reduce the 
risk of LGB in these patients while at the same time 
providing the maximal beneficial effect to the upper 
gastrointestinal tract.
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